Skip to main content

 9B4P | pdb_00009b4p

Tetramer Formation of the BCL11A ZF0 Domain


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.56 Å
  • R-Value Free: 
    0.294 (Depositor), 0.294 (DCC) 
  • R-Value Work: 
    0.278 (Depositor), 0.281 (DCC) 
  • R-Value Observed: 
    0.279 (Depositor) 

Starting Model: in silico
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9B4P

This is version 1.0 of the entry. See complete history. 

Literature

A tetramer of BCL11A is required for stable protein production and fetal hemoglobin silencing.

Zheng, G., Yin, M., Mehta, S., Chu, I.T., Wang, S., AlShaye, A., Drainville, K., Buyanbat, A., Bienfait, F., Tenglin, K., Zhu, Q., Orkin, S.H.

(2024) Science 386: 1010-1018

  • DOI: https://doi.org/10.1126/science.adp3025
  • Primary Citation Related Structures: 
    9B4P

  • PubMed Abstract: 

    Down-regulation of BCL11A protein reverses the fetal (HbF, α 2 γ 2 ) to adult (HbA, α 2 β 2 ) hemoglobin switch and is exploited in gene-based therapy for hemoglobin disorders. Because of reliance on ex vivo cell manipulation and marrow transplant, such therapies cannot lessen disease burden. To develop new small-molecule approaches, we investigated the state of BCL11A protein in erythroid cells. We report that tetramer formation mediated by a single zinc finger (ZnF0) is required for production of steady-state protein. Beyond its role in protein stability, the tetramer state is necessary for γ-globin gene repression, because an engineered monomer fails to engage a critical co-repressor complex. These aspects of BCL11A protein production identify tetramer formation as a vulnerability for HbF silencing and provide opportunities for drug discovery.


  • Organizational Affiliation: 
    • Dana-Farber/Boston Children's Hospital Cancer and Blood Disorder Center, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

Macromolecule Content 

  • Total Structure Weight: 33.06 kDa 
  • Atom Count: 2,252 
  • Modeled Residue Count: 279 
  • Deposited Residue Count: 280 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
B-cell lymphoma/leukemia 11A28Homo sapiensMutation(s): 0 
Gene Names: BCL11A, CTIP1, EVI9, KIAA1809, ZNF856
UniProt & NIH Common Fund Data Resources
Find proteins for Q9H165 (Homo sapiens)
Explore Q9H165 
Go to UniProtKB:  Q9H165
PHAROS:  Q9H165
GTEx:  ENSG00000119866 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9H165
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
ZN
(Subject of Investigation/LOI)

Query on ZN



Download:Ideal Coordinates CCD File
K [auth B]
L [auth C]
M [auth A]
N [auth D]
O [auth E]
K [auth B],
L [auth C],
M [auth A],
N [auth D],
O [auth E],
P [auth F],
Q [auth G],
R [auth H],
S [auth I],
T [auth J]
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.56 Å
  • R-Value Free:  0.294 (Depositor), 0.294 (DCC) 
  • R-Value Work:  0.278 (Depositor), 0.281 (DCC) 
  • R-Value Observed: 0.279 (Depositor) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 100.404α = 90
b = 58.311β = 134.122
c = 70.087γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Howard Hughes Medical Institute (HHMI)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2024-12-18
    Type: Initial release